This interest is fueled by post mortem and in vivo studies, including fluid biomarkers and PET imaging, which consistently show a relationship between tau pathology and cognitive impairment in the AD clinical spectrum.44, 45, 46. The gene discussed is MAPT; the disease is Alzheimer disease.